Fauce Steven R, Yang Otto O, Effros Rita B
Department of Pathology & Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1732, United States.
J Immunol Methods. 2007 Oct 31;327(1-2):75-81. doi: 10.1016/j.jim.2007.07.017. Epub 2007 Aug 8.
During HIV-1 infection, the CD8(+) T lymphocyte response is critical to controlling the virus; indeed, the development of AIDS results, in large part, from the eventual failure of this response. The ability to measure the composite CD8(+) T lymphocyte anti-viral activity is, therefore, an essential requirement in the evaluation of immune based therapies and potential vaccines. We report here the details of a reproducible assay that measures the ability of CD8(+) T lymphocytes to suppress viral production by infected autologous CD4(+) T lymphocytes. The assay is not limited to persons with any specific HLA type, and the use of bi-specific antibodies for cell expansion makes the assay feasible in situations where cell numbers may be limiting. The measurement of viral production over time provides a global readout of the CD8(+) T lymphocyte overall function against HIV-1, which can be used for longitudinal assessment of individual HIV-infected persons in order to evaluate therapy, immune reconstitution, and new vaccines.
在HIV-1感染过程中,CD8(+) T淋巴细胞反应对于控制病毒至关重要;事实上,艾滋病的发展在很大程度上源于这种反应最终的失败。因此,测量复合CD8(+) T淋巴细胞抗病毒活性的能力是评估基于免疫的疗法和潜在疫苗的一项基本要求。我们在此报告一种可重复检测方法的详细信息,该方法用于测量CD8(+) T淋巴细胞抑制受感染的自体CD4(+) T淋巴细胞产生病毒的能力。该检测方法不限于任何特定HLA类型的人群,并且使用双特异性抗体进行细胞扩增使得该检测方法在细胞数量可能有限的情况下可行。随着时间的推移对病毒产生进行测量,可全面了解CD8(+) T淋巴细胞针对HIV-1的整体功能,这可用于对个体HIV感染者进行纵向评估,以评估治疗效果、免疫重建情况和新型疫苗。